From FDA Watchdog to CEO: Verbois to Lead Rx-360's Supply Chain Overhaul

PHILADELPHIA, PA – July 14, 2026 – In a strategic move that underscores the critical vulnerabilities in the global pharmaceutical supply chain, the industry consortium Rx-360 has appointed Dr. S. Leigh Verbois, a distinguished former U.S. Food and Drug Administration (FDA) official, as its new Chief Executive Officer. The appointment, effective today, signals a pivotal shift for the organization, placing a seasoned regulator at the forefront of the industry's collaborative effort to ensure drug quality and patient safety.

Dr. Verbois's transition from federal oversight to industry leadership comes at a time of unprecedented strain. Persistent drug shortages, geopolitical tensions disrupting manufacturing, and the ever-present threat of counterfeit medicines have exposed deep structural weaknesses in the network that delivers life-saving therapies. For investors and executives, her appointment is a clear indicator that the industry is prioritizing regulatory acumen and a global perspective to build a more resilient future.

"I am thrilled to take on this role during this dynamic time in the pharmaceutical industry," Dr. Verbois stated, expressing her eagerness to work with the Rx-360 team "to protect patients through global collaboration across the pharmaceutical sector through optimization of existing capabilities and innovation in global supply chain security and integrity."

A Regulator’s Playbook for an Industry Challenge

Dr. Verbois is not an outsider to the intricate battles fought over supply chain integrity; for years, she was one of its chief strategists from within the government. Her resume reads like a roadmap of the FDA's most critical global and domestic security functions. As the former Director of the Office of Drug Security, Integrity and Response within the FDA's Center for Drug Evaluation and Research (CDER), she led the charge on everything from pharmaceutical import and export activities to recalls and supply chain compliance.

Her experience extends far beyond U.S. borders. Having served as Director of the FDA China Office in Beijing, she managed the delicate regulatory relationship between the two superpowers, giving her firsthand knowledge of the manufacturing landscape that produces a vast quantity of the world's Active Pharmaceutical Ingredients (APIs). This role, coupled with her leadership of the Office of Global Operations, where she guided diplomatic efforts to protect public health worldwide, provides her with a rare, ground-level understanding of the international complexities that can cripple supply chains.

Before joining Rx-360, she honed her focus on quality standards as the Senior Director of Global Regulatory and Laboratory Programs at the U.S. Pharmacopoeia (USP). There, she led strategies to advance supply chain resiliency, a role that directly complements Rx-360's mission. This deep well of experience in shaping policy, enforcing compliance, and fostering international cooperation is precisely the toolkit Rx-360 needs to navigate its next chapter.

Rx-360's Next Era: Data, AI, and Deeper Collaboration

Founded in 2009 in the wake of a heparin contamination crisis that exposed lethal gaps in the supply chain, Rx-360 has established itself as a vital hub for pre-competitive collaboration. Its membership roster includes over 80 of the world's leading pharmaceutical and biotech firms, including Pfizer, GSK, Johnson & Johnson, and Moderna. The consortium's flagship initiative, the Joint Audit Program® (JAP), has become an industry standard, allowing members to share the costs and results of supplier audits, dramatically reducing redundancy and enhancing oversight.

In 2023 alone, one supplier reported an estimated savings of $425,000 from licensing audit reports through the program, showcasing the tangible financial and operational benefits of this collaborative model. Now, under Dr. Verbois, Rx-360 plans to evolve this successful program. The strategic targets are clear: expand the JAP to address emerging risks, incorporate data-driven insights and artificial intelligence to enhance assessments, and create more outcome-oriented industry collaborations.

The push toward AI and data analytics is not just a nod to a popular trend; it is a strategic imperative. The pharmaceutical industry is grappling with a lack of real-time visibility across its sprawling networks. AI-powered predictive analytics can help anticipate demand spikes, identify potential disruptions before they occur, and monitor the fragile cold chain required for biologics and cell therapies. By embedding these technologies into its audit and assessment frameworks, Rx-360 aims to move the industry from a reactive to a proactive security posture.

A Global Veteran for a Globalized Battlefield

The timing of Dr. Verbois’s appointment is no coincidence. The pharmaceutical supply chain has become a key front in geopolitical maneuvering. Over-reliance on single geographic clusters for APIs, particularly in China and India, has created dangerous "choke points." Trade disputes, regional conflicts, or national policy shifts can sever access to critical raw materials, leading to the kind of widespread drug shortages that now last, on average, over five years, according to a recent USP report.

Dr. Verbois's experience managing the U.S.-China regulatory relationship and guiding strategy across Asia-Pacific, Africa, and the Middle East makes her uniquely suited to lead an organization whose battlefield is inherently global. Her understanding of cross-border regulatory harmonization and international diplomacy will be crucial as Rx-360 works to build a more diversified and transparent supply network. The organization has already been expanding its global footprint, recently becoming a Pilot Center of Excellence for the APEC Regulatory Harmonization Steering Committee to focus on supply chain integrity.

Dr. Kathleen Silva, Rx-360 Board Chair, emphasized this forward-looking vision, stating, "As CEO, Leigh will lead Rx-360 into its next phase of growth and impact. Building on our strong foundation, she will focus on evolving Rx-360... to better meet the increasingly complex needs of the global pharmaceutical industry." Her leadership is seen as essential to enhancing the consortium's relevance in an era defined by global risk and cross-border regulatory friction.

The industry recognizes that supply chain security is not a competitive advantage but a shared responsibility. By placing a leader with Dr. Verbois's global regulatory authority at the helm, Rx-360's influential members are making a powerful statement about their commitment to fortifying the pathways that connect medicines to patients.